![Motif Bio Plc](https://directorstalk.net/wp-content/uploads/2015/10/Motif-Bio.jpg)
Q&A with Dr Graham Lumsden Chief Executive Officer at Motif Bio Plc (LON:MTFB)
Motif Bio’s Dr Graham Lumsden discusses the manufacturing of the Iclaprim clinical trial supplies in this exclusive interview with DirectorsTalk
Motif Bio’s Dr Graham Lumsden discusses the manufacturing of the Iclaprim clinical trial supplies in this exclusive interview with DirectorsTalk
Purplebrick’s Michael Bruce discusses their IPO, the company’s background, the online market and how the £25 million fund raise will be spent in this exclusive DirectorsTalk interview
Ascent Resources’ Colin Hutchinson discusses the Petišovci project, IPPC permit and higher returns for the future in the exclusive interview with DirectorsTalk
Inspirit Energy’s John Gunn discusses the successful completion of internal testing for their Inspirit charger, the significance of this and the next steps for the company in this exclusive interview with DirectorsTalk
Savannah Resources’ David Archer discusses the significant copper resource potential identified within Blocks 4 and 5 in Oman in this exclusive DirectorsTalk interview
Northland Capital’s Vadim Alexandre discusses the Motif Bio Plc Iclaprim Phase III announcement in this exclusive interview with DirectorsTalk
ImmuPharma’s Tim McCarthy discusses the progress of Lupuzor, the key milestones for 2016 and a possible re-rating for ImmuPharma shares in this exclusive interview with DirectorsTalk
Goldplat’s Gerard Kisbey-Green discusses the completion of 2 additional capital projects, the weighbridge installation and progress in the New Year in this exclusive interview with DirectorsTalk
Arria NLG’s Wayne Thornhill discusses their year-end results ending 30th September 2015 in this exclusive interview with DirectorsTalk
Strat Aero’s Tony Dunleavy discusses their acquisition of Aero Kinetics, FAA certification and future transactions in this exclusive interview with DirectorsTalk